Drugs.com - New Drug Approvals

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-dssb; SB16; 120 mg vial), a biosimilar...

Feb 17, 2025 - 22:33
 0
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-dssb; SB16; 120 mg vial), a biosimilar...
Read More

Tags:

Previous Article

A Nifty Device Could One Day Turn Your Car’s Exhaust Into Electricity

Next Article

STAT+: STAT is backing up and monitoring CDC data in real time: See what’s changing

Related Posts

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatm...

Feb 9, 2025  0

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Sumitomo Pharma America Announces U.S. FDA Approval of ...

Feb 9, 2025  0

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for...

Feb 9, 2025  0